Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology

Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens

(2018) Mengjia Song et al.   Chinese Journal of Cancer Research

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

(2018) David Stenehjem et al.   OncoTargets and Therapy

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Cemiplimab: First Global Approval

(2018) Anthony Markham et al.   DRUGS

Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers

(2018) Ying L. Liu et al.   Current Oncology Reports

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

(2017) Mizuki Nishino et al.   Nature Reviews Clinical Oncology

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab

(2017) Udupi A. Ramagopal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2

(2017) Krzysztof M. Zak et al.   STRUCTURE

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

(2017) Shuguang Tan et al.   Nature Communications

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab

(2017) Fei Zhang et al.   Oncotarget

Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies

(2017) Mengnan He et al.   Oncotarget

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

(2017) Shuguang Tan et al.   Protein & Cell

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab

(2017) Hyun Tae Lee et al.   Scientific Reports

CTLA-4 and PD-1 Pathways

(2016) Elizabeth I. Buchbinder et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

(2016) Kefang Liu et al.   CELL RESEARCH

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

(2016) Zhenkun Na et al.   CELL RESEARCH

Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?

(2016) Matteo S. Carlino et al.   CLINICAL CANCER RESEARCH

Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant

(2016) Roberta Pascolutti et al.   STRUCTURE

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

(2016) Ju Yeon Lee et al.   Nature Communications

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1

(2016) Shoichiro Horita et al.   Scientific Reports

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Checkpoints

(2015) James P. Allison   CELL

PD-1/PD-L1 inhibitors

(2015) Joel Sunshine et al.   CURRENT OPINION IN PHARMACOLOGY

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

(2015) Giovanna Scapin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

(2015) Roy L. Maute et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

(2015) Giovanna Scapin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Nivolumab for the treatment of cancer

(2014) Anasuya Gunturi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

(2014) Yanping Xiao et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Antitumour immunity gets a boost

(2014) Jedd D. Wolchok et al.   NATURE

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies

(2014) Andrew J.S. Furness et al.   TRENDS IN IMMUNOLOGY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

(2013) Xiaoxiao Cheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy

(2013) H. Chen et al.   Cancer Immunology Research

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Migration of Th1 Lymphocytes Is Regulated by CD152 (CTLA-4)-Mediated Signaling via PI3 Kinase-Dependent Akt Activation

(2012) Karin Knieke et al.   PLoS One

Rigid-body Ligand Recognition Drives Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Receptor Triggering

(2010) Chao Yu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

A dimeric structure of PD-L1: functional units or evolutionary relics?

(2010) Yong Chen et al.   Protein & Cell

Epitope Landscape in Breast and Colorectal Cancer

(2008) N. H. Segal et al.   CANCER RESEARCH

CTLA-4 Activation of Phosphatidylinositol 3-Kinase (PI 3-K) and Protein Kinase B (PKB/AKT) Sustains T-Cell Anergy without Cell Death

(2008) Helga Schneider et al.   PLoS One

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

(2008) D. Y.-w. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

(2008) E. Lazar-Molnar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA